Johnson & Johnson said Wednesday a booster shot of its Covid-19 vaccine generated a promising immune response in early stage clinical trials – although the information equipped by the company in a press release was gentle on some details.
J&J’s vaccine requires greatest one dose and recipients are regarded as fully vaccinated two weeks after receiving the shot. The company said Wednesday that J&J recipients who obtained a booster dose of the shot generated virus-fighting antibodies “nine-fold larger” than those considered four weeks after a single dose.
Increases in antibody responses were noticed in vaccine trial participants between ages 18 and 55, the company said, and in those 65 years and older who obtained a decrease dosage of the booster shot.
A man receives a shot of Johnson & Johnson Covid-19 vaccine at a pop-up vaccination heart at the beach, in South Beach, Florida, on May 9, 2021.
Eva Marie Uzcategui | AFP | Getty Images
The implications are based on two Phase 1/2 research, according to the company.
“We have established that a single shot of our COVID-19 vaccine generates stable and sturdy immune responses that are durable and power by eight months,” Dr. Mathai Mammen, head of research and development at J&J’s Janssen vaccine arm, said in a statement.
“With these original data, we also witness that a booster dose of the Johnson & Johnson COVID-19 vaccine additional increases antibody responses among watch participants who had beforehand obtained our vaccine,” he added.
While the original data is promising, the company’s press release made no mention of the booster shots’ potential impact on the coronavirus delta variant or on safety.
When asked about data on delta, J&J referred CNBC to a document in July that confirmed a single dose of the vaccine generated a promising immune response to the variant.
It also raises questions about why J&J recipients want booster shots – especially after the July document confirmed that a single shot of its vaccine gives immunity that lasts at least eight months and appears to bring adequate protection against the fast-spreading delta variant.
To be certain that, the Facilities for Disease Regulate and Prevention has said J&J recipients will probably want a booster dose but added it would no longer have ample data correct now to strengthen a formal recommendation.
The company said Wednesday it is engaging with the Food and Drug Administration and assorted health authorities regarding booster shots.
The original data comes less than a week after J&J announced that Alex Gorsky was stepping down as CEO. Gorsky, 61, who was chairman and CEO for nine years, will change into govt chairman.